CTRI/2021/05/033846已完成未知
An open label, multicentre, multi-dose, single arm treatment clinical trial to determine the safety and efficacy of earth tea manufactured by martin Sinclair b4b corp, 40 remsen ave, Brooklyn, NY 11212, United states in human adult, patients with mild COVID-19. - EART-001-21
Martin Sinclair BB Corp0 个研究点目标入组 15 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 15
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •1.Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF); willingness and capability to complete all the study procedures.
- •2.Age 18-75 years (both inclusive) at the time of signing ICF.
- •3.Patients with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR (within 48 hours prior to randomization).
- •4.Patients with uncomplicated respiratory tract viral infection
- •5.For female patients: evidence of post-menopause or for Pre-menopause patients, negative pretreatment serum or urine pregnancy test.
- •6.Eligible patients of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 7 days following the last study treatment.
- •7.Not participating in any other interventional drug clinical studies before completion of the present study
- •8.Controlled diabetic patients with HbA1C limit < 7.0
- •9.Hypertension Patients up till Hypertension Stage 2 shall be included in the study (Systolic blood pressure at least 140mm Hg and Diastolic blood pressure at least 90 mm Hg)
- •10.Time interval between symptoms onset and randomization to no more than 7 days.
- •11.Pyrexia (axillary > 98.6°F or frontal >99.5°F); or/and any of the following symptoms:
- •Sore throat
- •Nasal congestion
- •Body aches and pains
- •12.Patients with Loss of smell and Taste.
排除标准
- •COVID - 19 patients with history or significant presence of the following will be excluded from participation/enrollment in the study trial:
- •1.Severe infection, defined as oxygen saturation (SPO2) <=93 % or arterial oxygen partial pressure (PaO2)/ fraction of inspired O2 (FiO2) <=300 mmH or need for invasive or non-invasive ventilator support, ECMO or shock requiring vasopressor support.
- •2.Requires ICU care for management of ongoing clinical status.
- •3.Participation in this study will not be in the best interest of the patient, or any other circumstances that prevent the patient from participating in the study safely.
- •4.Inability to intake or tolerate oral medications like refractory nausea, vomiting, or gastrointestinal disorders, or having undergone extensive bowel resection which may affect adequate absorption of the drug.
- •5.Known severe renal impairment [creatinine clearance (CrCl) <30 mL/min] or having received continuous renal replacement therapy, hemodialysis or peritoneal dialysis; CrCl is to be calculated by the following Cockcroft-Gault formula only when the serum creatinine is >1.5Ã?ULN.
- •6.patient has a serious chronic disease (e.g., human immunodeficiency virus (HIV), cancer requiring chemotherapy within the preceding 6 months, unstable cardiac, pulmonary (Asthma, chronic obstructive lung disease), neurologic, vascular, or endocrinologic disease states requiring medication dose adjustments within the last 30 days.
- •7.Psychiatric disease that is not well controlled (controlled defined as stable on a regimen for more than one year).
- •8.Known severely reduced LV function (Ejection fraction <30%)
- •9. Severe liver disease: underlying liver cirrhosis or Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevated over 5 times the ULN.
- •10. Gout/history of gout or hyperuricemia (above the ULN).
- •11. Pregnant or lactating women.
- •12. Having participated in any other interventional drug clinical study within 30 days prior to first dose of study drug.
- •13. Clinical prognostic non-survival, palliative care, and have no response to supportive treatment within three hours of admission.
- •14.Patients with diabetes having HbA1C limit > 7.0
- •15. Patients with Hypertensive crisis.
研究者
相似试验
进行中（未招募）
1 期
Transposon-manipulated Allogeneic CARCIK-CD19 cells in Pediatric and Adult Patients with r/r ALL post HSCTRelapsed or Refractory B cell Acute Lymphoblastic Leukemia after Haematopoietic Stem Cell TransplantationMedDRA version: 21.0Level: LLTClassification code 10063625Term: Acute lymphoblastic leukemia recurrentSystem Organ Class: 100000004864EUCTR2017-000900-38-ITFONDAZIONE TETTAMANTI M.DE MARCHI ONLUS21
进行中（未招募）
1 期
Stopping Eculizumab Treatment Safely in atypical Haemolytic Uraemic Syndrome (SETS aHUS)Atypical Haemolytic Uraemic Syndrome (aHUS)EUCTR2017-003916-37-GBewcastle Upon Tyne Hospitals NHS Foundation Trust50
Unknown
不适用
A study to evaluate efficacy and safety of stem cells in a condition involving severe obstruction of blood vessels of leg, particularly in smokersCTRI/2017/02/007836Stempeutics Research Pvt Ltd164
招募中
4 期
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab.Nervous System DiseasesPACTR202103563404333Genentech Inc.150
进行中（未招募）
1 期
Ease of Use and Safety of the New U300 Pen Injector in Insulin-Naïve Patients withT2DMType 2 diabetes mellitusMedDRA version: 17.0Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-001253-16-DESanofi-aventis recherche & développement